Evidence map›Paper›PMID 38858638›Full record

SynthesisBMC cancer2024

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients.

Francisco Cezar Aquino de Moraes, Renan Yuji Ura Sudo, Maria Eduarda Cavalcanti Souza, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Incidence of gynecological cancers following prolactin-increasing antipsychotic use: a population cohort study.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Francisco Cezar Aquino de MoraesOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Rua dos Mundurucus, n?4487, Belém, PA, 66073-000, Brazil. francisco.cezar2205@gmail.com.
Renan Yuji Ura SudoFederal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.ORCID http://orcid.org/0000-0001-8117-2784
Maria Eduarda Cavalcanti SouzaUniversity of Pernambuco, Recife, Pernambuco, Brazil.ORCID http://orcid.org/0000-0002-7244-6461
Marianne Rodrigues FernandesOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Rua dos Mundurucus, n?4487, Belém, PA, 66073-000, Brazil.ORCID http://orcid.org/0000-0002-1396-3442
Ney Pereira Carneiro Dos SantosOncology Research Center, University Hospital João de Barros de Barreto, Federal University of Pará, Rua dos Mundurucus, n?4487, Belém, PA, 66073-000, Brazil.ORCID http://orcid.org/0000-0001-8087-7037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFemale gynecological cancers represent a serious public health problem, with 1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often used in psychiatric disorders, including schizophrenia, bipolar disorder, and major depression. It is estimated that the prescription of these drugs is linked to 1,800 deaths a year in the United States, but their association with cancer remains controversial.

methodsWe searched PubMed, Scopus, and Web of Science databases for studies reporting the correlation in the incidence risk of gynecological cancer by antipsychotic use. We used DerSimonian and Laird random-effect models to compute logit transformed odds ratio (OR) for the primary binary endpoint with 95% confidence interval (CI). Heterogeneity was assessed through effect size width along with I-squared and Tau-squared statistics. Review Manager 5.4.1. was used for statistical analyses. A p-value of < 0.05 denoted statistically significant.

results50,402 patients were included, of whom 778 (1,54%) took antipsychotic medication for at least 1 year. 1,086 (2,15%) with ovarian cancer and 49,316 (97,85%) with endometrial cancer. Antipsychotic use (OR 1.50; 1.06 to 2.13 95% CI; p-value 0.02), hypertension (OR 1.50; 95% CI 1.06 to 2.13; p-value < 0.01), nulliparity (OR 1.98; 95% CI 1.53 to 2.57; p-value < 0.01) and multiparity (OR 0.53; 95% CI 0.41 to 0.69; p-value < 0.01) showed significantly different distributions between groups of cancer and cancer-free patients. The primary endpoint of incidence risk of gynecological cancer by antipsychotic therapy showed a statistically significant difference (OR 1.67; 95% CI 1.02 to 2.73; p-value < 0.05) against the use of antipsychotic drugs.

conclusionsOur meta-analysis showed that the use of antipsychotic drugs increases the risk of gynecological cancers, particularly endometrial cancer. This result should be weighed against the potential effects of treatment for a balanced prescribing decision.

Indexed as

Antipsychotic AgentsGenital Neoplasms, FemaleEndometrial NeoplasmsFemaleHumansIncidenceOdds RatioOvarian NeoplasmsRisk FactorsAntipsychotic AgentsAntipsychoticsDrug Side effectsEpidemiologyGynecological cancerIncidence

Identifiers

PMID38858638
PMCPMC11163728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.